Analyst Expectations for Cogent Biosciences's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Cogent Biosciences (NASDAQ:COGT) in the last quarter, with 5 bullish and 1 somewhat bullish ratings. The average 12-month price target for the company is $24.17, a decrease of 13.68% from the previous average price target of $28.00.
August 30, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have given bullish ratings for Cogent Biosciences, with an average 12-month price target of $24.17, down 13.68% from the previous target.
The bullish ratings from analysts indicate a positive outlook for Cogent Biosciences. However, the decrease in the average price target could suggest a potential slowdown in the company's growth or a reassessment of its value, which could impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100